A Case of IgA Vasculitis Presenting as Duodenal Perforation Presentation by Dr. Audrey Liu, at the Rheumatology Winter

Tweet Author

Tweet Content

A Case of IgA Vasculitis Presenting as Duodenal Perforation Presentation by Dr. Audrey Liu, at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/kZWgy1S0Wh https://t.co/9mJAzVRVpl

Links

A Case of IgA Vasculitis Presenting as Duodenal Perforation | RheumNow https://buff.ly/FFiEakN

Hydroxychloro-King (3.7.2025) Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past wee

Tweet Author

RheumNow

Tweet Content

Hydroxychloro-King (3.7.2025) Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow. https://t.co/83ZAyrrgg3 https://t.co/63cIdP559y

Links

Hydroxychloro-King (3.7.2025) | RheumNow https://buff.ly/f6VKVtW

Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL

Tweet Author

RheumNow

Tweet Content

Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to deucravacitinib in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 15 in 684 moderate-to-severe plaque PsO pts… https://t.co/GYK604kJ9u https://t.co/Ao1BpL1Qxt

Inorganic Pyrophosphate Levels In Severe Calcinosis Phenotype

The European Commission (EC) has approved Celltrion’s Avtozma (CT-P47), a biosimilar referencing Roche’s RoActemra (

Tweet Author

RheumNow

Tweet Content

The European Commission (EC) has approved Celltrion’s Avtozma (CT-P47), a biosimilar referencing Roche’s RoActemra (tocilizumab). https://t.co/ukMDwtgUhw https://t.co/htDVWKbu3n

Links

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases … https://buff.ly/6Gbmadd

Congratulations to Dr. Mehmet Hocaoglu (University of Pittsburgh) on being awarded a 2024 Rheumatoid Arthritis Research

Tweet Author

RheumNow

Tweet Content

Congratulations to Dr. Mehmet Hocaoglu (University of Pittsburgh) on being awarded a 2024 Rheumatoid Arthritis Research Program grant to investigate the unique and shared risk factors between patients with preclinical rheumatoid arthritis and patients with RA.… https://t.co/eF4yb3Hxsj https://t.co/MLNWKFiCiU

11 March 2025

Cardiovascular and Fracture Risk with Denosumab Versus Bisphosphonates in Dialysis Patients

Annals of Internal Medicine has published a Japanese administrative claims database study showing that, compared with oral bisphosphonates (BIS), denosumab (DEN) lowered fracture risk by 45%, but increased the risk for major adverse cardiac events (MACE) by 36%.

Cardiac concerns are heightened in dialysis patients, who also have high rates of fracture morbidity.

Meta-analysis shows the combination therapy bDMARD with MTX in #PsA pts yields better bDMARDs drug survival, especially

Tweet Author

RheumNow

Tweet Content

Meta-analysis shows the combination therapy bDMARD with MTX in #PsA pts yields better bDMARDs drug survival, especially with TNFi. 20 observational studies, 30,634 PsA pts. Insufficient data for non-TNFi bDMARDs. But adding MTX to bDMARDs had better TNFi survival (HR=0.79… https://t.co/3Y2cOzt3TQ https://t.co/6f8yiwMqAa

11 March 2025

Increased Mortality In Arthritis Patients with COPD

People with chronic obstructive pulmonary disease (COPD) and arthritis have a higher risk of death than people with arthritis who do not have COPD, according to a new study. The study is published in the January 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal.

Metanalysis of cancer risk w/ abatacept vs placebo or TNFi in #RA. (18 RCTs, 10 LTE, 15 535 PYs ABA exposure) show

Tweet Author

RheumNow

Tweet Content

Metanalysis of cancer risk w/ abatacept vs placebo or TNFi in #RA. (18 RCTs, 10 LTE, 15 535 PYs ABA exposure) show no signif increase in malignancy for ABA vs PBO (IRR 0.58) or TNFi (IRR 0.72). Observational data ABA > other b/tsDMARDs (IRR 1.21; 1.15–1.28), but not csDMARDs… https://t.co/2aBfwyKv0e https://t.co/zUmaHZN3mR

Topics

A Case of IgA Vasculitis Presenting as Duodenal Perforation Presentation by Dr. Audrey Liu, at the Rheumatology Winter

Hydroxychloro-King (3.7.2025) Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past wee

Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL

Inorganic Pyrophosphate Levels In Severe Calcinosis Phenotype

The European Commission (EC) has approved Celltrion’s Avtozma (CT-P47), a biosimilar referencing Roche’s RoActemra (

Congratulations to Dr. Mehmet Hocaoglu (University of Pittsburgh) on being awarded a 2024 Rheumatoid Arthritis Research

Meta-analysis shows the combination therapy bDMARD with MTX in #PsA pts yields better bDMARDs drug survival, especially

Metanalysis of cancer risk w/ abatacept vs placebo or TNFi in #RA. (18 RCTs, 10 LTE, 15 535 PYs ABA exposure) show

Do you get our email newsletter?